Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors

Current Pharmaceutical Design

Volumn 13, Issue 7, 2007, Pages 737-747

  Landriscina, Matteo ^a   Spadafora, Corrado ^b   Cignarelli, Mauro ^a   Barone, Carlo ^c  

^a UNIVERSITY OF FOGGIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anaplastic thyroid tumor; Differentiation; Hematological malignancies; Hormone therapy; Prostate tumor; Radiometabolic therapy; Reverse transcriptase; RT inhibitors

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; IODINE 131; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; RECOMBINANT THYROTROPIN; RETINOIC ACID; RNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERIT; STAVUDINE; TAXOID; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTINEOPLASTIC ACTIVITY; CATALYSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL; CYTOSTASIS; DNA SEQUENCE; DRUG EFFICACY; DRUG STRUCTURE; EMBRYONAL TISSUE; ENDOGENOUS RETROVIRUS; ENZYME ACTIVITY; ENZYME INHIBITION; EUKARYOTE; GENE EXPRESSION; GENE SILENCING; GENOME; HEMATOLOGIC MALIGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; MAMMAL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; RETROPOSON; RETROVIRUS; REVERSE TRANSCRIPTION; REVIEW; THYROID TUMOR; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34047092790     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780249191     Document Type: Review

References (102)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Leszczyniecka M, Roberts T, Dent P, Grant S, Fisher PB. Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 2001; 90: 105-56.
3. Mangiacasale R, Pittoggi C, Sciamanna I, Careddu A, Mattei E, Lorenzini R, et al. Exposure of normal and transformed cells to nevirapine, a reverse transcriptase inhibitors, reduces cell growth and promote differentiation. Oncogene 2003; 22: 2750-61.
4. Sciamanna I, Landriscina M, Pittoggi C, Quirino M, Mearelli C, Beraldi R, et al. Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. Oncogene 2005; 24: 3923-31.
5. Menendez-Arias L. Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 2002; 23: 381-3.
6. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256: 1783-90.
7. Balzarini J. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem Pharmacol 1999; 58: 1-27.
8. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol 2001; 312: 795-805.
9. Pomerantz RJ, Horn DL. Twenty years of therapy for HIV-1 infection. Nat Med 2003; 9: 867-73.
10. Lazzarin A. Enfuvirtide: the first HIV fusion inhibitor. Expert Opin Pharmacother 2005; 6: 453-64.
11. Munoz A, Schrager LK, Bacellar H, Speizer I, Vermund SH, Detels R, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. Am J Epidemiol 1993; 137: 423-38.
12. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Investigation. JAMA 1998; 280: 1497-503.
13. Bonnet F, Lewden C, May T, Heripret L, Jougla E, Bevilacqua S, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly antiretroviral therapy. Cancer 2004; 101: 317-24.
14. International Collaboration of HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92: 1823-30.
15. Rabkin CS. AIDS and cancer in the era of highly active antiretroviral therapy (HAART). Eur J Cancer 2001; 37: 1316-9.
16. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 2001; 37: 1188-201.
17. Tirelli U, Bernardi D, Spina M, Vaccher E. AIDS-related tumors: integrating antiviral and anticancer therapy. Crit Rev Oncol Hematol 2002; 41: 299-315.
18. Scadden DT. AIDS-related malignancies. Annu Rev Med 2003; 54: 285-303.
19. Rabkin CS, Testa MA, Huang J, Von Roenn JH. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr 1999; 21(Suppl 1): S31-3.
20. Nasti G, Martellotta F, Berretta M, Mena M, Fasan M, Di Perri G, et al; GICAT; ICONA. Impact of highly active antiretroviral therapy on the presenting features and outcome of patients with acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer 2003; 98: 2440-6.
21. Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, Chentsova N, et al. The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study. Cancer 2004; 100: 2644-54.
22. Cheung TW. AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive-the Trojan Horse is being destroyed"-Part A: Kaposi's sarcoma. Cancer Invest 2004; 22: 774-86.
23. Ebrahim SH, Abdullah AS, McKenna M, Hamers FF. AIDS-defining cancers in Western Europe, 1994-2001. AIDS Patient Care STDS 2004; 18: 501-8.
24. Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol 2005; 23: 1253-60.
25. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al, Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: association with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-32.
26. Bhaskaran K, Brettle R, Porter K, Walker AS; CASCADE Collaboration. Systemic non-Hodgkin lymphoma in individuals with known dates of HIV seroconversion: incidence and predictors. AIDS 2004; 18: 673-81.
27. Cheung TW. AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive-the Trojan Horse is being destroyed"-Part B: Malignant lymphoma. Cancer Invest 2004; 22: 787-98.
28. Orem J, Otieno MW, Remick SC. AIDS-associated cancer in developing nations. Curr Opin Oncol 2004; 16: 468-76.
29. Vaccher E, Spina M, Talamini R, Zanetti M, di Gennaro G, Nasti G, et al. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003; 37: 1556-64.
30. Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factor influencing survival in 111 patients. Cancer 2004; 100: 2627-36.
31. Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van Lunzen J, et al. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004; 125: 455-62.
32. Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrate sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IMS862 Study Team. J Clin Oncol 2005; 23: 990-8.
33. Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, et al. Prospective study of the effect of antiretroviral therapy on Kaposi sarcoma-associated herpesvirus infection in patients with and without Kaposi sarcoma. J Acquir Immune Defic Syndr 2002; 31: 384-90.
34. Navarro JT, Ribera JM, Oriol A, Vaquero M, Romeu J, Batlle M, et al. Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophoshamide, hydroxydoxorubicin, vincristin and prednisone. Br J Haematol 2001; 112: 909-15.
35. Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, et al; AIDS Malignancy Consortium. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001; 19: 2171-8.
36. Holkova B, Takeshita K, Cheng DM, Volm M, Wasserheit C, Demopoulos R, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001; 19: 3848-51.
37. Aoki Y, Tosato G. Neoplastic conditions in the context of HIV-1 infection. Curr HIV Res 2004; 2: 343-9.
38. Thiessard F, Morlat P, Marimoutou C, Labouyrie E, Ragnaud JM, Pellegrin JL, et al. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidemiologie Clinique du SIDA ed Aquitaine (GECSA). Cancer 2000; 88: 1696-702.
39. Cattelan AM, Calabro ML, Gasperini P, Aversa SM, Zanchetta M, Meneghetti F, et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001; 28: 44-9.
40. Einstein MH, Kadish AS. Anogenital neoplasia in AIDS. Curr Opin Oncol 2004; 16: 455-62.
41. Ahdieh-Grant L, Li R, Levine AM, Massad LS, Strickler HD, Minkoff H, et al. Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 2004; 96: 1070-6.
42. Panther LA, Schlecht HP, Dezube BJ. Spectrum of human papillomavirus-related dysplasia and carcinoma of the anus in HIV-infected patients. AIDS Read 2005; 15: 79-82, 85-6, 88, 91.
43. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I, Cornforth D, et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004; 18: 485-93.
44. Monini P, Sgadari C, Toschi E, Barillari G, Ensoli B. Antitumour effects of antiretroviral therapy. Nat Rev Cancer 2004; 4: 861-75.
45. Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17: F17-22.
46. Stebbing J, Portsmouth S, Nelson M, Mandalia S, Kandil H, Alexander N, et al. The efficacy of ritonavir in the prevention of AIDS-related Kaposi's sarcoma. Int J Cancer 2004; 108: 631-3.
47. Pantanowitz L, Dezube BJ. Advances in the pathobiology and treatment of Kaposi sarcoma. Curr Opin Oncol 2004; 16: 443-9.
48. Stebbing J, Gazzard B, Mandalia S, Teague A, Waterston A, Marvin V, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin lymphoma. J Clin Oncol 2004; 22: 2177-83.
49. Stadler RF, Gregorcyk SG, Euhus DM, Place RJ, Huber PJ, Simmang CL. Outcome of HIV-infected patients with invasive squamous-cell carcinoma of the anal canal in the era of highly active antiretroviral therapy. Dis Colon Rectum 2004; 47: 1305-9.
50. Powles T, Powles J, Nelson M, Sandison A, Peston D, Buchannan J, et al. Head and neck cancer in patients with human immunodeficiency virus-1 infection: incidence, outcome and association with Epstein-Barr virus. J Laryngol Otol 2004; 118: 207-12.
51. International human genome mapping consortium. Nature 2001; 409: 934-41.
52. Deininger PL, Moran JV, Batzer MA, Kazazian HH. Mobile elements and mammalian genome evolution. Curr Opin Genet Dev 2003; 13: 651-8.
53. Kazazian HH. Mobile elements: drivers of genome evolution. Science 2004; 303: 1626-32.
54. Friedlander A, Patarca R. Endogenous proviruses. Crit Rev Oncog 1999; 10: 129-59.
55. Voytas DF, Boeke JD. In: Craig NL, Craigie R, Gellert M, Lambowitz AM Ed, Mobile DNA II. American Society for Microbiology, Washington, DC. 2002; 631-62.
56. Brouha B, Schustak J, Badge RM, Lutz-Prigge S, Farley AH, Moran JV, et al. Hot L1s account for the bulk of retrotransposition in the human population. Proc Natl Acad Sci USA 2003; 100: 5280-5.
57. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. Nat Rev Genet 2002; 3: 370-9.
58. Ostertag EM, Kazazian HH. Biology of mammalian L1 retrotransposons. Annu Rev Genet 2001; 35: 501-38.
59. Orgel LE, Crick FH. Selfish DNA: the ultimate parasite. Nature 1980; 284: 604-7.
60. Brosius J, Tiedge H. Reverse transcriptase: mediator of genomic plasticity. Virus Genes 1995; 11: 163-79.
61. Moran JV, DeBerardinis RJ, Kazazian HH Jr. Exon shuffling by L1 retrotransposition. Science 1999; 283: 1530-4.
62. Nekrutenko A, Li WH. Transposable elements are found in a large number of human protein-coding genes. Trends Genet 2001; 17: 619-21.
63. Tomilin NV. Control of genes by mammalian retroposons. Int Rev Cytol 1999; 186: 1-48.
64. Ferrigno O, Virolle T, Djabari Z, Ortonne JP, White RJ, Aberdam D. Transposable B2 SINE elements can provide mobile RNA polymerase II promoters. Nat Genet 2001; 28: 77-81.
65. Speek M. Antisense promoter of human L1 retrotransposon drives transcription of adjacent cellular genes. Mol Cell Biol 2001; 21: 1973-85.
66. Whitelaw E, Martin DI. Retrotransposons as epigenetic mediators of phenotypic variation in mammals. Nat Genet 2001; 27: 361-5.
67. Spadafora C. Endogenous reverse transcriptase: a mediator of cell proliferation and differentiation. Cytogenet Genome Res 2004; 105: 346-50.
68. Poznanski AA, Calarco PG. The expression of intracisternal A particole genes in the preimplantation mouse embryo. Dev Biol 1991; 143: 271-81.
69. Packer AI, Manova K, Bacharova RF. A discrete LINE-1 transcript in mouse blastocysts. Dev Biol 1993; 157: 281-3.
70. Mwenda JM. Biochemical characterization of a reverse transcriptase activity associated with retroviral-like particles isolated from human placental villous tissue. Cell Mol Biol 1993; 39: 317-28.
71. Kiessling AA, Crowell R, Fox C. Epididymis is a principal site of retrovirus expression in the mouse. Proc Acad Natl Sci USA 1989; 86: 5109-13.
72. Branciforte D, Martin SL. Developmental and cell-type specificity of Line-1 expression in mouse testis - implications for transposition. Mol Cell Biol 1994; 14: 2584-92.
73. Nilsson BO, Kattstrom PO, Sundstrom P, Jaquemin P, Larsson E. Human oocytes express murine retroviral equivalents. Virus Genes 1992; 6: 221-7.
74. Giordano R, Magnano AR, Zaccagnini G, Pittoggi C, Moscufo N, Lorenzini R, et al. Reverse transcriptase activity in mature spermatozoa of mouse. J Cell Biol 2000; 148: 1107-13.
75. Sciamanna I, Barbieri L, Martire A, Pittoggi C, Beraldi R, Giordano R, et al. Sperm endogenous reverse transcriptase as mediator of new genetic information. Biochem Biophys Res Commun 2003; 312: 1039-46.
76. Deragon JM, Sinnett D, Labuda D. Reverse transcriptase activity from human embryonal carcinoma cells NTera2D1. EMBO J 1990; 9: 3363-8.
77. Martin SL. Ribonucleoprotein particles with LINE-1 RNA in mouse embryonal carcinoma cells. Mol Cell Biol 1991; 11: 4804-7.
78. Pittoggi C, Sciamanna I, Mattei E, Beraldi R, Lobascio AM, Mai A, et al. Role of endogenous reverse transcriptase in murine early embryo development. Mol Reprod Dev 2003; 66: 225-36.
79. Hagan CR, Rudin CM. Mobile elements activation and genotoxic cancer therapy: potential clinical implications. Am J Pharmacogenomics 2002; 2: 25-36.
80. Hagan CR, Sheffield RF, Rudin CM. Human Alu element retrotrasposition induced by genotoxic stress. Nat Genet 2003; 35: 219-20.
81. Li TH, Schmid CW. Differential stress induction of individual Alu loci: implication for transcription and retrotransposition. Gene 2001; 276: 135-41.
82. Khan AS, Muller J, Sears JF. Early detection of endogenous retroviruses in chemically induced mouse cells. Virus Res 2001; 79: 39-45.
83. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001; 20: 6958-68.
84. Blasco MA, Lee HW, Hande MP, Samper E, Lansdorp PM, DePinho RA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34.
85. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004; 91: 483-90.
86. van Leenders GJ, Schalken JA. Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. Clin Rev Oncol Hematol 2003; 46: S3-10.
87. van Leenders GJ, Aalders TW, Hulsbergen-van de Kaa CA, Ruiter DJ, Schalken JA. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J Pathol 2001; 195: 563-70.
88. Ain KB. Management of undifferentiated thyroid cancer. Clin Endocrinol Metab 2000; 4: 615-29.
89. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10: 587-94.
90. Landriscina M, Fabiano A, Altamura S, Bagalá C, Piscazzi A, Cassano A, et al. Reverse transcriptase inhibitors downregulate cell proliferation in vitro and in vivo and restore TSH signaling and iodine uptake in human thyroid anaplastic carcinoma. J Clin Endocrinol Metab 2005; 90(10): 5663-71.
91. Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328-35.
92. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, et al. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998; 391: 815-8.
93. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002; 295: 1079-82.
94. Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980; 77: 2936-40.
95. Asou H, Koike M, Elstner E, Cambell M, Le J, Uskokovic MR, et al. 19-nor vitamin-D analogs: a new class of potent inhibitors of proliferation and inducers of differentiation of human myeloid leukemia cell lines. Blood 1998; 92: 2441-9.
96. Xing M, Usadel H, Cohen Y, Tokumaru Y, Guo Z, Westra WB, et al. Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res 2003; 63: 2316-21.
97. Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/ I-symporter gene methylation status. J Clin Endocrinol Metab 1999; 84: 2449-57.
98. Yamanaka M, Watanabe M, Yamada Y, Takagi A, Murata T, Takahashi H, et al. Altered methylation of multiple genes in carcinogenesis of the prostate. Int J Cancer 2003; 106: 382-7.
99. Tsutsumida A, Hamada J, Tada M, Aoyama T, Furuuchi K, Kawai Y, et al. Epigenetic silencing of E- and P-cadherin gene expression in human melanoma cell lines. Int J Oncol 2004; 25: 1415-21.
100. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11(14): 1805-43.
101. Basavapathruni A, Anderson KS. Developing novel nonnucleoside HIV-1 reverse transcriptase inhibitors: beyond the butterfly. Curr Pharm Des 2006; 12(15): 1857-65.
102. Silvestri R, Artico M. Indolyl aryl sulfones (IASs): development of highly potent NNRTIs active against wt-HIV-1 and clinically relevant drug resistant mutants. Curr Pharm Des 2005; 11(29): 3779-806.